Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the context of neoplasms predominantly occurs during fasting or the postabsorptive state.

Hypoglycemia can arise as an adverse reaction to various oral therapies, with insulin therapy posing the greatest risk. Factors contributing to hypoglycemia include insulin dose mismatches, increased insulin sensitivity, and concurrent conditions such as adrenal or pituitary insufficiency. This presents a significant risk that must be carefully balanced against the benefits of glucose control, particularly in the elderly population.

The initial response to hypoglycemia involves reducing endogenous insulin secretion, followed by releasing counterregulatory hormones such as epinephrine, norepinephrine, glucagon, growth hormone, and cortisol. Symptoms manifest when plasma glucose levels reach 60-70 mg/dL (3.3-3.9 mM), including sweating, hunger, paresthesias, palpitations, tremors, anxiety, and autonomic symptoms. Severe hypoglycemia can lead to neurological symptoms, seizures, and coma.

In diabetic patients, the glucagon secretory response to hypoglycemia may become deficient over time, increasing the risk of severe hypoglycemia, especially in those with hypoglycemia unawareness and autonomic neuropathy. Home glucose monitoring is crucial in documenting hypoglycemia, enabling timely intervention and management.

Treatment options for hypoglycemia involve the administration of oral glucose, intravenous glucose, or glucagon, particularly when oral intake is not feasible. Glucagon, produced via recombinant DNA technology, interacts with the glucagon GPCR on target cells, activating the Gs-cAMP-PKA pathway. It is prescribed for individuals at risk of severe hypoglycemia and is administered intravenously, intramuscularly, or subcutaneously, with the intramuscular route being preferred in emergencies. Following the initial response to glucagon, patients should consume oral glucose or food to prevent recurrent hypoglycemia.

Overall, the management of hypoglycemia demands a meticulous understanding of its causes, symptoms, and appropriate therapeutic interventions, ensuring the safety and well-being of affected individuals.

Bölümden 25:

article

Now Playing

25.16 : Hypoglycemia and Glucagon

Insulin and Hypoglycemic Drugs

64 Görüntüleme Sayısı

article

25.1 : Glukoz Homeostazı: Kan Şekerinin Düzenlenmesi

Insulin and Hypoglycemic Drugs

866 Görüntüleme Sayısı

article

25.2 : Glukoz Homeostazı: Pankreas Adacıkları ve İnsülin Sekresyonu

Insulin and Hypoglycemic Drugs

654 Görüntüleme Sayısı

article

25.3 : İnsülin: Reseptör ve Sinyal Yolları

Insulin and Hypoglycemic Drugs

709 Görüntüleme Sayısı

article

25.4 : Diyabet Patofizyolojisi

Insulin and Hypoglycemic Drugs

506 Görüntüleme Sayısı

article

25.5 : Diyabet: Belirtileri, Tanısı ve Komplikasyonları

Insulin and Hypoglycemic Drugs

364 Görüntüleme Sayısı

article

25.6 : Diyabet: Yönetim ve Farmakoterapi

Insulin and Hypoglycemic Drugs

138 Görüntüleme Sayısı

article

25.7 : İnsülin: Biyosentez, Kimya ve Hazırlama

Insulin and Hypoglycemic Drugs

160 Görüntüleme Sayısı

article

25.8 : İnsülin Formülasyonları: Türleri ve Dağıtımı

Insulin and Hypoglycemic Drugs

76 Görüntüleme Sayısı

article

25.9 : İnsülin: Doz Rejimi ve Yan Etkileri

Insulin and Hypoglycemic Drugs

63 Görüntüleme Sayısı

article

25.10 : Oral Hipoglisemik Ajanlar: Sülfonilüreler

Insulin and Hypoglycemic Drugs

75 Görüntüleme Sayısı

article

25.11 : Oral Hipoglisemik Ajanlar: Biguanidler ve Glitazonlar

Insulin and Hypoglycemic Drugs

80 Görüntüleme Sayısı

article

25.12 : Oral Hipoglisemik Ajanlar: Glinidler

Insulin and Hypoglycemic Drugs

56 Görüntüleme Sayısı

article

25.13 : Oral Hipoglisemik Ajanlar: α-Glukozidaz İnhibitörleri

Insulin and Hypoglycemic Drugs

60 Görüntüleme Sayısı

article

25.14 : Glukagon Benzeri Reseptör Agonistleri

Insulin and Hypoglycemic Drugs

113 Görüntüleme Sayısı

See More

JoVE Logo

Gizlilik

Kullanım Şartları

İlkeler

Araştırma

Eğitim

JoVE Hakkında

Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır